{
  "paper": {
    "doi": null,
    "pmcid": "PMC12780394",
    "title": "Global bibliometric analysis of pleural mesothelioma biomarkers (2002\u20132024): trends and emerging frontiers",
    "authors": [
      "Not specified"
    ],
    "journal": "Journal of Thoracic Disease",
    "year": 2025,
    "study_type": "bibliometric analysis",
    "eco_type": null
  },
  "extraction_provenance": {
    "extraction_pipeline": {
      "name": "medlit_pass1_extract",
      "version": "0.1.0",
      "git_commit": "b806ec36126690c24218bfa2f6999b594dcf4d10",
      "git_commit_short": "b806ec3",
      "git_branch": "ingest-refactor",
      "git_dirty": true,
      "repo_url": "https://github.com/org/medlit"
    },
    "models": {
      "llm": {
        "name": "claude-sonnet-4-20250514",
        "version": ""
      }
    },
    "prompt": {
      "version": "v1",
      "template": "medlit_extraction_v1",
      "checksum": "sha256:f94cc0ab23940d18"
    },
    "execution": {
      "timestamp": "2026-02-23T17:41:05.745628Z",
      "hostname": "unknown",
      "python_version": "3.13.3",
      "duration_seconds": 41.96
    },
    "entity_resolution": null,
    "model_info": null
  },
  "entities": [
    {
      "id": "disease_1",
      "class": "Disease",
      "name": "pleural mesothelioma",
      "synonyms": [
        "PM",
        "malignant pleural mesothelioma",
        "malignant mesothelioma"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": "C0812413",
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "disease_2",
      "class": "Disease",
      "name": "mesothelioma",
      "synonyms": [
        "mesothelial tumor",
        "mesothelial neoplasm"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": "C0025500",
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "gene_1",
      "class": "Gene",
      "name": "mesothelin",
      "synonyms": [
        "MSLN"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": "HGNC:7371",
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "gene_2",
      "class": "Gene",
      "name": "BAP1",
      "synonyms": [
        "BRCA1-associated protein 1"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": "HGNC:950",
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "gene_3",
      "class": "Gene",
      "name": "PD-L1",
      "synonyms": [
        "programmed cell death ligand-1",
        "CD274"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": "HGNC:17635",
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "gene_4",
      "class": "Gene",
      "name": "osteopontin",
      "synonyms": [
        "OPN",
        "SPP1",
        "secreted phosphoprotein 1"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": "HGNC:11255",
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "gene_5",
      "class": "Gene",
      "name": "miR-182-5p",
      "synonyms": [
        "microRNA-182-5p"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": "HGNC:31568",
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "gene_6",
      "class": "Gene",
      "name": "let-7b",
      "synonyms": [
        "microRNA let-7b"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": "HGNC:31476",
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "drug_1",
      "class": "Drug",
      "name": "nivolumab",
      "synonyms": [],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": "1312830",
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "drug_2",
      "class": "Drug",
      "name": "ipilimumab",
      "synonyms": [],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": "1094833",
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "drug_3",
      "class": "Drug",
      "name": "pembrolizumab",
      "synonyms": [],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": "1547545",
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "drug_4",
      "class": "Drug",
      "name": "pemetrexed",
      "synonyms": [],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": "282464",
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "exposure_1",
      "class": "Environmental_Factor",
      "name": "asbestos",
      "synonyms": [
        "asbestos exposure"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "biomarker_1",
      "class": "Biomarker",
      "name": "SMRP",
      "synonyms": [
        "soluble mesothelin-related peptide"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "biomarker_2",
      "class": "Biomarker",
      "name": "sPD-L1",
      "synonyms": [
        "soluble PD-L1"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "biomarker_3",
      "class": "Biomarker",
      "name": "microRNA",
      "synonyms": [
        "miRNA",
        "miR"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "treatment_1",
      "class": "Treatment",
      "name": "immunotherapy",
      "synonyms": [
        "immune checkpoint inhibitors",
        "ICIs"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "treatment_2",
      "class": "Treatment",
      "name": "CAR-T therapy",
      "synonyms": [
        "chimeric antigen receptor T-cell therapy"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    }
  ],
  "evidence_entities": [
    {
      "id": "paper_1:background:1:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "background_1",
      "text": "Pleural mesothelioma (PM) is an aggressive malignancy that originates on the mesothelial surface of the pleura, peritoneum, pericardium, and tunica vaginalis. Due to the absence of specific clinical symptoms, early-stage diagnosis occurs in fewer than 5% of cases.",
      "confidence": 0.95,
      "extraction_method": "llm",
      "study_type": "bibliometric analysis",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "paper_1:introduction:2:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "introduction_2",
      "text": "The predominant risk factor for PM is asbestos exposure, with approximately 80% of cases linked to prior asbestos contact.",
      "confidence": 0.95,
      "extraction_method": "llm",
      "study_type": "bibliometric analysis",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "paper_1:discussion:3:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "discussion_3",
      "text": "Mesothelin is one of the widely studied biomarkers of PM, which is expressed at low levels in normal cells and undetectable in normal tissues, but is abundantly expressed in malignant mesothelioma, pancreatic cancer, ovarian cancer, lung cancer, and other cancers.",
      "confidence": 0.9,
      "extraction_method": "llm",
      "study_type": "bibliometric analysis",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "paper_1:discussion:4:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "discussion_4",
      "text": "SMRP are the only biomarkers for PM approved by the U.S. Food and Drug Administration (FDA).",
      "confidence": 0.95,
      "extraction_method": "llm",
      "study_type": "bibliometric analysis",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "paper_1:discussion:5:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "discussion_5",
      "text": "The PD-L1 protein plays a central role in the antitumor immune response.",
      "confidence": 0.9,
      "extraction_method": "llm",
      "study_type": "bibliometric analysis",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "paper_1:discussion:6:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "discussion_6",
      "text": "miRNAs affect tumor growth, invasion and angiogenesis by binding to mRNAs, thereby influencing the expression of oncogenes and oncogenes and the activity of signaling pathways.",
      "confidence": 0.85,
      "extraction_method": "llm",
      "study_type": "bibliometric analysis",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "paper_1:discussion:7:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "discussion_7",
      "text": "For chimeric antigen receptor T-cell (CAR-T) therapy, mesothelin represents a relatively suitable target. It exhibits low expression in normal mesothelial tissue yet is overexpressed in the majority of epithelial-type PM.",
      "confidence": 0.9,
      "extraction_method": "llm",
      "study_type": "bibliometric analysis",
      "eco_type": null,
      "source": "extracted"
    }
  ],
  "relationships": [
    {
      "subject": "exposure_1",
      "predicate": "INCREASES_RISK",
      "object": "disease_1",
      "evidence_ids": [
        "paper_1:introduction:2:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.95,
      "properties": {
        "percentage": "80%"
      },
      "section": "introduction",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "gene_1",
      "predicate": "INDICATES",
      "object": "disease_1",
      "evidence_ids": [
        "paper_1:discussion:3:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.9,
      "properties": {
        "expression_pattern": "overexpressed"
      },
      "section": "discussion",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "biomarker_1",
      "predicate": "INDICATES",
      "object": "disease_1",
      "evidence_ids": [
        "paper_1:discussion:4:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.95,
      "properties": {
        "regulatory_status": "FDA approved"
      },
      "section": "discussion",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "gene_3",
      "predicate": "ASSOCIATED_WITH",
      "object": "treatment_1",
      "evidence_ids": [
        "paper_1:discussion:5:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.9,
      "properties": {
        "role": "antitumor immune response"
      },
      "section": "discussion",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "biomarker_3",
      "predicate": "ASSOCIATED_WITH",
      "object": "disease_1",
      "evidence_ids": [
        "paper_1:discussion:6:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.85,
      "properties": {
        "mechanism": "tumor growth, invasion and angiogenesis"
      },
      "section": "discussion",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "gene_1",
      "predicate": "ASSOCIATED_WITH",
      "object": "treatment_2",
      "evidence_ids": [
        "paper_1:discussion:7:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.9,
      "properties": {
        "target_suitability": "suitable target"
      },
      "section": "discussion",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "drug_1",
      "predicate": "TREATS",
      "object": "disease_1",
      "evidence_ids": [],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.8,
      "properties": {
        "combination": "with ipilimumab"
      },
      "section": "results",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "drug_2",
      "predicate": "TREATS",
      "object": "disease_1",
      "evidence_ids": [],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.8,
      "properties": {
        "combination": "with nivolumab"
      },
      "section": "results",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "drug_3",
      "predicate": "TREATS",
      "object": "disease_1",
      "evidence_ids": [],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.8,
      "properties": {
        "trial": "KEYNOTE-028"
      },
      "section": "results",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "biomarker_1",
      "predicate": "SAME_AS",
      "object": "gene_1",
      "evidence_ids": [],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.9,
      "properties": {},
      "section": "discussion",
      "asserted_by": "llm",
      "resolution": null,
      "note": "SMRP is derived from mesothelin"
    }
  ],
  "notes": [
    "This bibliometric analysis covers 662 publications on pleural mesothelioma biomarkers from 2002-2024",
    "The study identifies immunotherapy and epigenetics as emerging research hotspots",
    "SMRP is currently the only FDA-approved biomarker for pleural mesothelioma"
  ]
}